Abstract
Depression, anxiety, delirium, and other psychiatric symptoms are highly prevalent in the cancer setting, and pharmacological intervention is an important component in the overall psychosocial care of the patient. Psychopharmacology is also used as a primary or adjuvant treatment for the management of cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. Psychiatrists, oncologists, and palliative care physicians working as members of a multidisciplinary team have the opportunity to target multiple symptoms that negatively affect a patient’s quality of life with the strategic use of psychotropic medications when deemed appropriate. This article aims to review the indications for use of antidepressants, psychostimulants, anxiolytics, antipsychotics, and mood stabilizers in oncology. An updated review of the relevant literature is discussed and referenced in each section.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Mitchell AJ et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–74.
Pirl WF, Roth AJ. Diagnosis and treatment of depression in cancer patients. Oncology (Williston Park). 1999;13(9):p. 1293–301. Discussion 1301–2, 1305–6.
Holland JC et al. Distress management. J Natl Compr Canc Netw. 2013;11(2):190–209.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders DSM-5, 5th edn. American Psychiatric Association, Washington, DC
Lee BN et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11(5):279–92.
Thekdi SM IM, Dunn L. Psychopharmacological interventions. In: Grassi RM, editor. Clinical psych-oncology: an international perspective. Chichester: Wiley-Blackwell; 2012. p. 109–26.
Desplenter F et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study. Br J Cancer. 2012;107(9):1644–51.
Ng CG et al. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22(4):762–7.
Caruso R et al. Psychopharmacology in psycho-oncology. Curr Psychiatry Rep. 2013;15(9):393.
Grassi L et al. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry. 2014;26(1):44–62. This review article includes a search of the major databases (MEDLINE, Embase, PsycLIT, PsycINFO, the Cochrane Library) and summarizes relevant data concerning the efficacy and safety of pharmacotherapy for cancer-related psychiatric disorders in cancer patients across the trajectory of the disease.
McDaniel JS et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995;52:89–99.
Sharpe M et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer. 2004;90(2):314–20.
Strouse TB. Psychopharmacologic treatment of depression in patients with cancer: a 2013 update. FOCUS 2013. 2013;11:450–9.
Stockler MR, O’Connell R, Nowak AK, et al. Effects of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol. 2007;8:603–12.
Miller AH. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2008;65(9):p. 732–741.
Danzer R, O’Connor J, Freund GG. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.
Tynan RJ et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26(3):469–79.
Mun AR et al. Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2013;33(9):3691–7.
De Fazio P et al. Mental adjustment to cancer: the role of anxious and depressive symptoms under treatment. Int J Psychiatry Med. 2013;46(4):375–86.
Strong V et al. Management of depression for people with cancer 4 (SMaRT oncology 1): a randomised trial. Lancet. 2008;372(9632):40–8.
Holland JC et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998;7(4):291–300.
Fisch MJ et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21(10):1937–43.
Schillani G et al. Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: report of 18 cases. Tumori. 2011;97(3):358–61.
Lydiatt WM et al. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol-Head Neck Surg. 2013;139(7):p. 678–686. This is an interesting study suggesting that certain depressive states can be prevented, in turn abutting the issue of whether certain depressive states in cancer may be explained by biochemically identifiable mechanisms such as inflammation.
Callari A et al. Treatment of depression in patients with breast cancer: a critical review. Tumori. 2013;99(5):p. 623–633. This article reviews the relevant evidence for the efficacy of SSRIs in breast cancer. The importance of the study is that it separates certain forms of pharmacologically treatable depression from general distress in cancer patients.
Kim SW et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62(1):75–83.
Moss EL et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006;15(3):259–67.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.
Smith EM et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.
Amr YM, Yousef AA. Evaluation of efficacy of the perioperative administration of venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clin J Pain. 2010;26(5):381–5.
Durand JP et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5.
L’Esperance S et al. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21(5):1461–74.
Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology. 2011;88(5–6):333–9.
Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70(12):1688–97.
Kelly CM et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br Med J. 2010;340.
Regan MM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441–51.
Rae JM et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452–60.
Zembutsu H et al. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011;11(2):185–93.
Ahmad A, Shahabuddin S, Sheikh S. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther. 2010;88(6):814–7.
Portenoy RK et al. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326–36.
Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manag. 1998;16(3):193–8.
Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37(1):57–62.
Bruera E et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain. 1992;50(1):75–7.
Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005;30(2):100–7.
Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care. 2012;29(6):483–90.
Minton O et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7, CD006704.
Roth AJ et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010;116(21):5102–10.
Bruera E et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013;31(19):2421–7.
Moraska AR et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673–9.
Jean-Pierre P et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.
Spathis A et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014;32(18):1882–8.
Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–14.
Yoon HJ et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013;13:240.
Boettger S, Breitbart W. An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Palliat Support Care. 2011;9(4):351–7.
Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin. 2008;24(4):657–722. vii.
Wang HR, Woo YS, Bahk WM. Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci. 2013;67(5):p. 323–31. This paper reviews six prospective, randomized controlled studies evaluating the efficacy, safety, and tolerability of atypical antipsychotics in the treatment of delirium.
Yoon HK et al. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica. 2011;23(4):179–83.
Anderson R et al. Lurasidone for the management of intensive care unit (ICU)-associated delirium. Crit Care Med. 2012;40(12):1–328.
Teslyar P et al. Prophylaxis with antipsychotic medication reduces the risk of post-operative delirium in elderly patients: a meta-analysis. Psychosomatics. 2013;54(2):p. 124–31. This paper reviews five studies examining the use of antipsychotics (haloperidol, risperidone, and olanzapine) in the prevention of postoperative delirium in elderly patients. Pooled analysis revealed a relative risk reduction of 50 % versus placebo.
Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics. 2009;50(2):159–61.
Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Care. 2013;30(1):75–82.
Han C et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13(7):851–70.
Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010;30(9):942–51.
McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013;27(2):132–5.
Smith HH. Palliative Medicine. Philadelphia: Saunders Elsevier; 2009. p. 894–8.
Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014;22(4):1143–51.
Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010;18(8):951–6.
Rahman T et al. Antipsychotic treatment in breast cancer patients. Am J Psychiatry. 2014;171(6):p. 616–21. This paper reviews the issue of prescribing antipsychotics in the context of breast cancer, a concern often raised by patients to their clinicians requiring the most up-to-date information.
Leucht S et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
Linden W et al. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2–3):343–51.
Noyes R, Holt C, Massie M. Anxiety disorders. In: Holland J, editor. Psycho-oncology. New York: Oxford University Press; 1998. p. 548–63.
Miller K, Massie MJ. Depression and anxiety. Cancer J. 2006;12(5):388–97.
Prieto JM et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002;20(7):1907–17.
Lavigne JE et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat. 2012;136(2):479–86.
Lindgren ME et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013;22(8):p. 1889–94. The results of this study suggest that beta-blocker use may benefit cancer patients’ psychological adjustment following diagnosis, and provide a promising direction for future investigations on the pharmacological benefits of beta-blockers for cancer-related distress.
Dundar Y et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004;19(5):305–22.
Terzano MG et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):261–82.
Moore TA, Berger AM, Dizona P. Sleep aid use during and following breast cancer adjuvant chemotherapy. Psychooncology. 2011;20(3):321–5.
Costantini C, Ale-Ali A, Helsten T. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011;14(5):563–6.
Joffe H et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17(5):908–16.
Candy B et al. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane Database Syst Rev. 2012;10:Cd004596.
Testa A et al. Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases. Eur Rev Med Pharmacol Sci. 2013;17 Suppl 1:65–85.
Vaidya R et al. Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients. Oncology. 2011;81(1):p. 9–11. This study reports the percentage of breast cancer survivors (almost 8 %) receiving ongoing benzodiazepines and the circumstances surrounding their usage following 1000 consecutive women with breast cancers.
Altamura AC et al. Mood stabilizers for patients with bipolar disorder: the state of the art. Expert Rev Neurother. 2011;11(1):85–99.
Kargiotis O, Markoula S, Kyritsis AP. Epilepsy in the cancer patient. Cancer Chemother Pharmacol. 2011;67(3):489–501.
Eisenberg E et al. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 2007;67(9):1265–89.
Petrini M, Azzara A. Lithium in the treatment of neutropenia. Curr Opin Hematol. 2012;19(1):52–7.
Khasraw M et al. Using lithium as a neuroprotective agent in patients with cancer. BMC Med. 2012;10:131.
Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother. 2007;7(1):9–16.
Andersohn F et al. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology. 2010;75(4):335–40.
Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg. 2013;118(4):859–65.
Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 2008;30(8):1385–407.
Loprinzi CL, Barton DL, Qin R. Nonestrogenic management of hot flashes. J Clin Oncol. 2011;29(29):3842–6.
Loprinzi CL et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28(4):641–7.
Bar Ad V. Gabapentin for the treatment of cancer-related pain syndromes. Rev Recent Clin Trials. 2010;5(3):174–8.
Bennett MI et al. Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013;14(11):1681–8.
Anand S. Gabapentin for pruritus in palliative care. Am J Hosp Palliat Care. 2013;30(2):192–6.
Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583–9.
Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012;46(3):424–9.
Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;12, CD006044.
Bendaly EA et al. Topiramate in the treatment of neuropathic pain in patients with cancer. Support Cancer Ther. 2007;4(4):241–6.
Reas DL, Grilo CM. Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs. 2014;19:99–142.
Argyriou AA et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67(12):2253–5.
Compliance with Ethics Guidelines
Conflict of Interest
Seema M. Thekdi, Antolin Trinidad, and Andrew Roth declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Complex-Medical Psychiatric Issues
Rights and permissions
About this article
Cite this article
Thekdi, S.M., Trinidad, A. & Roth, A. Psychopharmacology in Cancer. Curr Psychiatry Rep 17, 529 (2015). https://doi.org/10.1007/s11920-014-0529-x
Published:
DOI: https://doi.org/10.1007/s11920-014-0529-x